ABC Transporter Protein-mediated Multidrug Resistance in Breast Cancer and Development of Targeting Strategies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multidrug resistance (MDR) significantly challenges breast cancer (BrCa) treatment, leading to reduced efficacy and increased recurrence.
• The molecular mechanisms of MDR are complex, involving ABC drug transporter efflux, altered drug metabolism, and the tumor microenvironment.
• Abnormal expression of ABC transporter proteins is a critical driver of MDR in BrCa.

Purpose of the Study:

• To review the roles of P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP) in BrCa MDR.
• To explore factors influencing ABC transporter expression and function, including breast cancer stem cells (BCSCs), epigenetic changes, and the tumor microenvironment.
• To highlight strategies for overcoming MDR, such as gene modification, novel drug development, and modulation of cell membrane lipids.

Main Methods:

• Literature review focusing on ABC transporters (P-gp, MRP1, BCRP) in breast cancer.
• Analysis of factors affecting transporter expression and function.
• Synthesis of current strategies to combat MDR.

Main Results:

• P-gp, MRP1, and BCRP are key ABC transporters implicated in BrCa MDR.
• BCSCs, epigenetic alterations, cell membrane lipids, and microenvironmental factors modulate ABC transporter activity.
• Various strategies are being investigated to overcome MDR.

Conclusions:

• Targeting ABC transporters and associated factors is essential for improving BrCa treatment efficacy.
• A multifaceted approach involving genetic, pharmacological, and lipid-modulating strategies holds promise for resolving MDR.
• Further research into the complex interplay of factors driving MDR is necessary for clinical advancement.